In 648 mostly biopsy-naive men with PI-RADS ≥3 lesions in China, cognitive fusion targeted biopsy was non-inferior to software fusion for detecting clinically significant prostate cancer (32% vs 34%; risk difference -1.02 points), though software did better at BMI ≥24.
RCTn = 648
He et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION)